IMCgp100 is an ImmTAC therapeutic targeting the melanoma-associated antigen gp100. It is currently undergoing a pivotal clinical study as a monotherapy for the treatment of patients with metastatic uveal melanomas.
Combination studies with IMCgp100 and other immunotherapies, including a Phase I/II study with checkpoint inhibitors durvalumab and tremelimumab from MedImmune (AstraZeneca), for patients with metastatic cutaneous melanoma, are currently recruiting.
IMCgp100 has been granted Orphan Drug Designation by the US Food and Drug Administration (FDA) for the treatment of uveal melanoma.
For more information on clinical trials involving IMCgp100 see clinicaltrials.gov.
Immunocore has established a comprehensive and regulatory approved preclinical assessment package for ImmTAC molecules to minimize the potential risks of treatment-related toxicities. The process comprises both molecular and cellular analyses and is predictive of clinical observations.